<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Shanghai Junshi Biosciences Co., Ltd. Class A — News on 6ix</title>
    <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd</link>
    <description>Latest news and press releases for Shanghai Junshi Biosciences Co., Ltd. Class A on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 27 May 2026 01:19:04 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/shanghai-junshi-biosciences-co-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836457c78dffbe2df150e94.webp</url>
      <title>Shanghai Junshi Biosciences Co., Ltd. Class A</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd</link>
    </image>
    <item>
      <title>Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-primary-endpoints-met-in-final-analysis-of-phase-3-study-for-perioperative-toripalimab-plus-chemotherapy-for-resectable-stage-ii-iii-nsclc</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-primary-endpoints-met-in-final-analysis-of-phase-3-study-for-perioperative-toripalimab-plus-chemotherapy-for-resectable-stage-ii-iii-nsclc</guid>
      <pubDate>Wed, 27 May 2026 01:19:04 GMT</pubDate>
      <description>Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-approval-of-toripalimab-nda-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-approval-of-toripalimab-nda-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma</guid>
      <pubDate>Thu, 21 May 2026 10:28:00 GMT</pubDate>
      <description>SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug application (NDA) for toripalimab in combination with disitamab vedotin for patients with HER2-expressing (which is defined as achieving a score of 1+, 2+ or 3+ in HER2 immunohistochemistry test), locally adv</description>
    </item>
    <item>
      <title>Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-presents-results-from-js207-pd-1vegf-bsab-phase-2-combo-studies-and-js212-egfrher3-adc-fih-phase-12-study-at-aacr-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-presents-results-from-js207-pd-1vegf-bsab-phase-2-combo-studies-and-js212-egfrher3-adc-fih-phase-12-study-at-aacr-2026</guid>
      <pubDate>Mon, 20 Apr 2026 21:00:00 GMT</pubDate>
      <description>SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that early clinical results from four studies across its innovative pipeline were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, featuring: the recombinant humanized anti-EGFR/HER3 bisp</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-2025-full-year-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-2025-full-year-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Fri, 13 Mar 2026 13:54:00 GMT</pubDate>
      <description>SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2025 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue of Junshi Biosciences was approximately RMB2,498 million in 2025, representing an increase of approximately</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-nmpa-acceptance-of-new-drug-applications-for-toripalimab-injection-subcutaneous-across-12-indications</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-nmpa-acceptance-of-new-drug-applications-for-toripalimab-injection-subcutaneous-across-12-indications</guid>
      <pubDate>Mon, 09 Mar 2026 13:00:00 GMT</pubDate>
      <description>SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug applications (the “NDAs”) for the company’s product, toripalimab injection (subcutaneous injection [code: JS001sc]), for 12 indications in the treatment of tumors has been accepted by the National Medical P</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-strategic-collaboration-with-antengene-to-evaluate-combination-therapy-with-js207-pd-1vegf-bsab-and-atg-037-oral-cd73-inhibitor</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-strategic-collaboration-with-antengene-to-evaluate-combination-therapy-with-js207-pd-1vegf-bsab-and-atg-037-oral-cd73-inhibitor</guid>
      <pubDate>Wed, 25 Feb 2026 00:30:00 GMT</pubDate>
      <description>SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has entered into the strategic collaboration with Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential o</description>
    </item>
    <item>
      <title>Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/toripalimab-presents-long-term-survival-benefits-as-1st-line-treatment-for-advanced-nasopharyngeal-carcinoma-and-esophageal-squamous-cell-carcinoma-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/toripalimab-presents-long-term-survival-benefits-as-1st-line-treatment-for-advanced-nasopharyngeal-carcinoma-and-esophageal-squamous-cell-carcinoma-patients</guid>
      <pubDate>Sat, 06 Dec 2025 03:11:00 GMT</pubDate>
      <description>Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%.Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st line treatment of R/M NPC.The final OS analysis of JUPITER-06 confirms the sustained survival benefit with toripalimab plus chemothera</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-acceptance-of-the-nda-for-roconkibart-il-17a-for-the-treatment-of-moderate-to-severe-plaque-psoriasis</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-acceptance-of-the-nda-for-roconkibart-il-17a-for-the-treatment-of-moderate-to-severe-plaque-psoriasis</guid>
      <pubDate>Fri, 05 Dec 2025 15:19:00 GMT</pubDate>
      <description>SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug application (“NDA”) for the company’s product, roconkibart injection (a recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005), for the treatment of adult patients with moderat</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-primary-endpoints-met-in-js001scs-phase-3-study-for-the-1st-line-treatment-of-nsq-nsclc</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-primary-endpoints-met-in-js001scs-phase-3-study-for-the-1st-line-treatment-of-nsq-nsclc</guid>
      <pubDate>Tue, 25 Nov 2025 01:24:00 GMT</pubDate>
      <description>SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab injection (subcutaneous injection) (code: JS001s</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-fdas-approval-of-ind-application-for-phase-23-clinical-study-of-js207-for-the-neoadjuvant-treatment-of-nsclc-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-fdas-approval-of-ind-application-for-phase-23-clinical-study-of-js207-for-the-neoadjuvant-treatment-of-nsclc-patients</guid>
      <pubDate>Fri, 17 Oct 2025 00:23:00 GMT</pubDate>
      <description>SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the investigational new drug (“IND”) application for an open-label, two-arm, randomized, active-controlled, phase 2/3 clinical study comparing the company’s product, recombinant humanized anti-PD-1/VEGF bispecific antibo</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-the-phase-3-study-of-js005-il-17a-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-met-primary-endpoints</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-the-phase-3-study-of-js005-il-17a-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-met-primary-endpoints</guid>
      <pubDate>Sun, 07 Sep 2025 12:30:00 GMT</pubDate>
      <description>SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that company’s product, recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-2025-interim-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-2025-interim-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Wed, 27 Aug 2025 02:18:00 GMT</pubDate>
      <description>SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2025 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTS As of June 30, 2025, the total revenue of Junshi Biosciences was approximately RMB1,168 million for the first half of 2025, representin</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma</guid>
      <pubDate>Fri, 08 Aug 2025 12:00:00 GMT</pubDate>
      <description>SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (“sNDA”) for toripalimab (trade name: TUOYI®) in combination with disitamab vedotin, an antibody-drug conjugate (“ADC”) developed by RemeGen Co., Ltd. as the treatment of HER2-expres</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces Ongericimab’s sNDA Approval in China</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-ongericimabs-snda-approval-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-ongericimabs-snda-approval-in-china</guid>
      <pubDate>Tue, 27 May 2025 12:00:00 GMT</pubDate>
      <description>SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (the “NMPA”) has approved two supplemental new drug applications for the ongericimab injection (a recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JU</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma</guid>
      <pubDate>Fri, 25 Apr 2025 11:43:00 GMT</pubDate>
      <description>SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (“NDA”) for toripalimab (trade name: TUOYI®) as the first-line treatment for unresectable or metastatic melanoma has been approved by the National Medical Products Administration (“</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-2024-full-year-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-2024-full-year-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Sat, 29 Mar 2025 01:35:00 GMT</pubDate>
      <description>SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue of Junshi Biosciences was approximately RMB1,948 million in 2024, representing an increase of approximately</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces Toripalimab’s Approval in Singapore</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-toripalimabs-approval-in-singapore</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-toripalimabs-approval-in-singapore</guid>
      <pubDate>Thu, 27 Mar 2025 01:00:00 GMT</pubDate>
      <description>SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the “NDA”) for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery</description>
    </item>
    <item>
      <title>Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma</title>
      <link>https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-approval-of-snda-for-toripalimab-in-combination-with-bevacizumab-for-1st-line-treatment-of-advanced-hepatocellular-carcinoma</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-junshi-biosciences-co-ltd/news/junshi-biosciences-announces-approval-of-snda-for-toripalimab-in-combination-with-bevacizumab-for-1st-line-treatment-of-advanced-hepatocellular-carcinoma</guid>
      <pubDate>Mon, 24 Mar 2025 03:53:00 GMT</pubDate>
      <description>SHANGHAI, March 23, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for the company’s product, toripalimab, in combination with bevacizumab for the first-line treatment of u</description>
    </item>
  </channel>
</rss>